*Refresh the page if the below document does not appear.
Biological E receives DCGI's approval to manufacture, and commercialize new vaccine
Hyderabad-based pharmaceutical and vaccine manufacturer Biological E has received the approval of the DCGI to manufacture and market a 14-valent pediatric Pneumococcal Conjugate Vaccine (Investigational Pneumococcal Polysaccharide Conjugate Vaccine PCV14) against S. pneumoniae infection.
Haryana state to ask DCGI for joint inspection of Maiden Pharma's premises
After the laboratory tests of the control samples did not show any proof of contamination of the syrups which were manufactured by Sonepatbased Maiden Pharmaceuticals, the State Drug Controller is going to a letter to the DCGI for a joint inspection of the facility’s premises.
Ferring Pharma gets USFDA nod for first gene therapy for bladder cancer
The US Food and Drug Administration approved Swiss-based drug major Ferring Pharma’s first gene therapy indicated for the treatment of adult patients with a type of bladder cancer.
Sun Pharma says FDA's warning letter states cGMP violations at Halol facility
Several days after Sun Pharma’s Halol unit was placed under import alert over cGMP violations by the US FDA, the company announced that they have received a warning letter from the authority listing the violations at the plant in Gujarat.
Gland Pharma's shares dips after management informed about challenging next 6 quarters
On Friday, Gland Pharma’s shares dropped 3% after the management informed the analysts that the next 6 quarters will remain ‘challenging’ for the company. Though the competitive intensity in the US will worsen this but the supply issues will be solved in the next few months.
Tel Aviv University researchers show success of potential one-time vaccine to treat HIV/AIDS
Tel Aviv University (TAU) in collaboration nwith researchers from Israel and the US demonstrated the success of a novel technology by using CRISPR system that has the potential to be developed into a one-time vaccine to treat patients suffering from HIV/AIDS.
Eli Lilly enters GPCR pact with Sosei Group for $731 Million
According to the agreement announced on
Friday, Eli Lilly will pay $37 million in cash
upfront to gain the right to nominate several
GPCR targets. Japan-based Sosei Group will
then handover selective small molecule
candidates for further development and
commercialization.
